Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 51079-767

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 51079-767). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium Extended-release 250 mg Tablets Unit Carton Label (Image 01)

Label for Divalproex Sodium Extended-Release Tablets, USP 250 mg, oral film-coated extended-release tablets. The label indicates 80 tablets per package and highlights valproic acid activity. Manufactured by Mylan Pharmaceuticals Inc. in Morgantown, WV. Includes storage instructions and a barcode.*

FDA Label Image

Divalproex Sodium 500 mg Tablets Unit Carton Label (Image 02)

Blue film-coated extended-release tablet unit-dose packaging for Divalproex Sodium by Mylan Institutional Inc. The label includes precautions about child resistance, institutional use, and light resistance, with instructions to check the lot number and expiration date through a window. The packaging shows the Mylan logo and distribution information.*

FDA Label Image

Divalproex Structural Formula (Image 03)

Chemical structure diagram showing the molecular structure of divalproex sodium, the active ingredient in Divalproex Sodium tablets. The image depicts the arrangement of atoms and bonds within the divalproex sodium molecule.*

FDA Label Image

Figure 1: Proportion Of Patients Achieving Any Particular Level Of Improvement Was Consistently Higher For Valproate Than For Placebo (Image 04)

A line graph showing percent reduction in CPS rate versus percent of patients for Divalproex Sodium Delayed-Release compared to placebo. The graph illustrates improvement or worsening effects, with solid and dashed lines representing Divalproex Sodium and placebo, respectively.*

FDA Label Image

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)

A cumulative distribution plot showing the percent reduction in CPS rate versus percent of patients for high dose and low dose Divalproex Sodium delayed release. The graph indicates improvement or worsening of CPS rate with labeled axes and corresponding solid and dashed lines for high and low doses, respectively.*

FDA Label Image

Figure 3: Mean Reduction In 4-week Migraine Headache Rates (Image 06)

A bar graph comparing the effects of placebo and Divalproex Sodium Extended-Release Tablets. The vertical axis measures a variable with values from 0 to 1.2. The placebo group shows a value of 0.6, while the bar for Divalproex Sodium Extended-Release Tablets reaches 1.2, marked with an asterisk indicating statistical significance (p=0.006).*

FDA Label Image

Unit Carton (Image 07)

Label for Divalproex Sodium Extended-Release Tablets, USP, 500 mg film-coated oral tablets. The label shows the dosage strength of 500 mg valproic acid activity and indicates a package size of 80 tablets (10 blister packs of 8). Manufactured by Mylan Pharmaceuticals Inc. The label includes dosing instructions to take once daily and storage temperature guidelines.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.